How innovative approaches to early stage clinical trial design can guarantee you late stage success

Accelerate early identification & selection of your most promising compounds

Download Brochure | Register Now

Now is the time for you to increase the efficiency of your early stage clinical development program. With rising R&D costs & decreasing approval rates, optimizing your approach to early stage clinical development has never been more important. Do you have a plan in place?

Despite the difficulties of getting this right, there are several cutting edge approaches to early stage clinical development that are being adopted by leading drug developers to dramatic effect. The Early Stage Clinical Development Summit delivers 18 leading drug developer speakers prepared to give you practical, robust advice that will help you identify your go/no-go candidates quicker allowing your company deliver in this notoriously difficult period of development.

The Early Stage Clinical Development Summit will bring together the leading drug developers, service providers & clinicians to discuss how to ensure you focus your efforts on your most promising candidates minimizing drug attrition in late development.  

Attend this meeting and you will:

• Learn how to design efficient strategies to successfully develop safety biomarkers as useful indicators of pharmacodynamic end points with MedImmune, Roche and Amgen.
• Gain an industry perspective from Sanofi and Novartis into how you can efficiently outsource your drug development program to minimize costs
• Understand how Johnson and Johnson are using a data driven approach to drug development can help you to identify your go/no go targets earlier avoiding costly failures further down the pipeline
• Understand how to better translate preclinical data into clinical development to minimise drug attrition rates with AstraZeneca
• Discover how to get ROI from your proof of concept and biomarker strategies with insight from Merck

The Expert Speaker Lineup Includes:

• Johan Luthman, Vice President R&D, Merck
• Alan Xiao, Director Clinical Pharmacology, AstraZeneca
• Jonathan Deutsch, Therapeutic Area Safety Head for Oncology, Johnson & Johnson
• David Geho, Senior Biomarker and Experimental Medicine Leader, Roche
• Gangadhar Sunkara, Director Translation Sciences, GSK
• Joe Reynolds, Senior Scientist, Merrimack Pharmaceuticals
• Mike Hale, Executive Director, Amgen
• Tharak Rao, Head of Medical Group, Novartis
• Rebecca Taub, CEO, Madrigal Pharmaceuticals
• Satjit Brar, Division of Pharmacometrics, CDER-Office of Clinical Pharmacology, FDA
• Kenneth Olivier, Director of Toxicology, Merrimack Pharmaceuticals
• Terry Walker, Director, Translational Immunology, Pfizer
• Deborah DiNoto, Director of Drug Development Outsourcing, & Preclinical Safety, Sanofi
• Christine DeMaria, Senior Scientist, Genzyme
• Aaron Nelson, Group Head of Translational Biomarkers Toxicology, Novartis
• Rakesh Dixit, DABT Vice President, R&D; Global Head Biologics Safety Assessment, MedImmune
• Jerry Galluppi, Director, Clinical Pharmacology and Pharmacometrics, Biogen Idec

Download the brochure now for more information.

The Early Stage Clinical Development Summit is being co-located with the Late Stage Clinical Development meeting.

Both meetings will take place at the Revere Hotel Boston, 29th May-1st June. Featuring unparallelled networking opportunities and the chance to attend presentations from both meetings, join us in Boston to hear from industry leaders on the hottest topics in drug development. For more information, please email: info@hansonwade.com

What’s next? 

Download the brochure to see more detail on the topics being covered

Something you want to share; white papers, articles or interested in speaking? Then let us know... just email any questions to info@hansonwade.com 

Get the best rates by booking now to ensure your place at this unique meeting - Book online or call +1 212 537 5898.